# A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

> **NCT02513459** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 65 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Risankizumab 600 mg IV
- **DRUG:** Risankizumab 180 mg SC

## Key facts

- **NCT ID:** NCT02513459
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-16
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-06-19
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2020-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02513459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02513459, "A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02513459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*